Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

icer. "While reported gross margin on product revenues for the third quarter was 51%, adjusted for the deferral of $1.6 million in revenues related to our Pfizer collaboration, gross margin would have been 55%."

The Company had approximately $21.8 million in cash and cash equivalents at September 30, 2008. Cash used in operations for the first nine months of 2008 was $13.0 million.

HIV Tropism Testing

"Monogram's enhanced Trofile Assay, introduced earlier this year with a thirty-fold improvement in sensitivity, has allowed a very important new analysis of Pfizer Inc.'s phase III trial of Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic HIV-1, known as the 'MERIT' study," said William Young, Monogram chief executive officer. "Data reported this week by Pfizer demonstrated that in this study, increased efficacy was shown as a result of the enrichment of the patient population by use of the enhanced version of Monogram's Trofile(TM) Assay." Results of the reanalysis of the "MERIT" trial were reported this week at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC.

Pfizer's HIV medication Selzentry (maraviroc) is approved for use in treatment-experienced individuals with R5-tropic HIV-1. In July 2007 Pfizer reported data from the phase III trial of Selzentry in treatment naive individuals ("MERIT"), in which patients had been selected for treatment by Monogram's Trofile Assay. The reported differences in outcome for individuals treated with Selzentry did not meet a predefined study endpoint of non-inferiority to an established first line treatment regimen. To week 48, 65% of individuals receiving Selzentry had HIV-1 RNA <50 copies/mL, compared to 69% of those individuals in the control arm of the trial.

In June 2008 Monogram introduced an enhanced sensitivity version of the Trofile Assay, with 30-fold greater sensitivity to detect low-level X4 HIV compared
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 ... , , , , , ... , Cell type , ...
... Kits , , ... Eppendorf Perfectprep Plasmid DNA Isolation Kits are designed to generate , ... automated fluorescent , sequencing, transfection, PCR, and other extremely ... In order to compare yields between our kits and the leading competitor, ...
... , Other important parameters for optimizing electroporation., , , , , , ... , Pulse length , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , ...
Cached Biology Technology:Actinomyces viscosus 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 3Optimizing electroporation parameters 2
(Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability in ... that occurs when the regions of the brain ... The use of non-invasive functional neuroimaging tools has ... dyslexia. However, most prior work has focused on ... a gap in our understanding of how multiple ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Dyslexic readers have disrupted network connections in the brain 2
... National data indicate that milk consumption has declined ... nutritional quality has more than doubled. Although this suggests ... in children,s diets, a new study suggests that in ... related to changes in their consumption of sodas and ...
... at the California Institute of Technology (Caltech) pioneered ... the immune system and neurodevelopmental disorders such as ... postmortem brains and of individuals with autism, as ... between alterations in the immune system and autism ...
... is a vital nutrient for pig growth, but pigs ... the University of Illinois has determined how adding various ... how pigs digest the phosphorus in four different feed ... bottom lines as well as for the environment. ...
Cached Biology News:Sugar-sweetened drinks are not replacing milk in kid's diets 2Sugar-sweetened drinks are not replacing milk in kid's diets 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3Helping pigs to digest phosphorus 2Helping pigs to digest phosphorus 3
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
... gun system, 220-240 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: